Mundipharma announces EU regulatory submission for Nyxoid
Mundipharma have submitted a marketing authorisation application for Nyxoid (intranasal naloxone 1.8 mg in 0.1 ml) to the European Medicines Agency (EMA), seeking approval for the emergency reversal of opioid overdose.
